How do I calculate the TyG index?

Formula: TyG = ln[(fasting TG in mg/dL × fasting glucose in mg/dL) / 2]. Step 1: Multiply fasting TG (mg/dL) by fasting glucose (mg/dL). Step 2: Divide the result by 2. Step 3: Take the natural logarithm (ln) of the result. Example: TG = 150 mg/dL, glucose = 100 mg/dL: ln(150 × 100 / 2) = ln(7500) = 8.92. Both values must be from a fasting sample.

What is TyG index and NAFLD?

TyG is significantly elevated in patients with non-alcoholic fatty liver disease (NAFLD/MASLD) and correlates with histological NAFLD severity. A meta-analysis (Wu et al., J Hepatol 2020) confirmed TyG as an independent predictor of NAFLD. Proposed mechanisms: insulin resistance drives hepatic de novo lipogenesis and TG accumulation. TyG may serve as an inexpensive, non-invasive proxy for identifying patients who need liver ultrasound, elastography, or hepatology referral in high-risk populations (obesity, T2DM, dyslipidemia).

What is TyG index and cardiovascular risk?

Elevated TyG is associated with increased cardiovascular risk through multiple mechanisms: insulin resistance promotes atherogenic dyslipidemia (small dense LDL, low HDL), endothelial dysfunction, inflammation, and thrombogenesis. Meta-analyses (Sanchez-Garcia et al., Cardiovasc Diabetol 2020) confirm TyG predicts major adverse cardiovascular events (MACE) independently of traditional risk factors in several populations. TyG also predicts coronary artery calcium score progression and peripheral artery disease.

What is TyG index in PCOS?

Polycystic ovary syndrome (PCOS) affects 8-13% of reproductive-age women and is strongly associated with insulin resistance even in normal-weight women. TyG is elevated in PCOS patients compared to controls and correlates with hyperinsulinemia, hyperandrogenism severity, and anovulatory cycle frequency. TyG can help quantify the metabolic insulin resistance component of PCOS, guiding decisions about metformin therapy, lifestyle modification intensity, and monitoring for type 2 diabetes progression.

How can I reduce my TyG index?

TyG can be reduced by lowering fasting triglycerides and improving fasting glucose: (1) Diet: reduce refined carbohydrates, sugar, alcohol (major TG drivers); Mediterranean or low-carb diet reduces both TG and glucose. (2) Exercise: 150 min/week aerobic exercise improves insulin sensitivity and lowers TG. (3) Weight loss: even 5-7% body weight reduction significantly improves TyG. (4) Medications: SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 agonists (semaglutide, liraglutide) reduce both TG and glucose. Fibrates or omega-3 fatty acids reduce TG if >500 mg/dL.

What is TyG-BMI index?

TyG-BMI is a modified version of TyG that multiplies TyG by BMI to incorporate visceral adiposity: TyG-BMI = TyG × BMI. Studies suggest TyG-BMI provides better discrimination for metabolic syndrome, NAFLD, and insulin resistance than TyG alone, because BMI captures the independent contribution of obesity to insulin resistance beyond the lipid-glucose axis. TyG-BMI is used in some research publications but is not yet a standard clinical tool.

What are the limitations of TyG index?

Key TyG limitations: (1) No universally validated clinical cutoff — thresholds vary by study, population, and ethnicity; (2) Requires confirmed fasting sample — non-fasting values are invalid; (3) Not validated as a clinical treatment target in RCTs; (4) Does not distinguish hypertriglyceridemia subtypes (familial vs. secondary) from insulin resistance; (5) Secondary causes of elevated TG (hypothyroidism, medications, alcohol) can inflate TyG without true insulin resistance; (6) Does not capture all dimensions of insulin resistance (e.g., hepatic vs. peripheral resistance). Interpret TyG alongside clinical context, not in isolation.

What medications affect TyG index?

Medications that raise TyG: corticosteroids (raise glucose and TG), antipsychotics (raise glucose, TG, and BMI), beta-blockers (raise TG, impair glucose metabolism), thiazide diuretics (raise glucose and TG), protease inhibitors for HIV. Medications that lower TyG: SGLT2 inhibitors (lower glucose and modestly lower TG), GLP-1 agonists (lower glucose and TG), fibrates (markedly lower TG), omega-3 fatty acids (lower TG), metformin (lower glucose). When interpreting TyG in a patient on multiple medications, consider medication effects on both TG and glucose.

Online Medical Tools — TyG Index

Printed on 9/2/2026

For informational purposes only. This is not medical advice.

Cardiology

TyG Index

The TyG index is a simple surrogate marker of insulin resistance derived from fasting triglycerides and fasting plasma glucose. It correlates with clamp-derived insulin resistance and is commonly used in cardiometabolic research and risk stratification.

Formula: TyG = ln((Triglycerides [mg/dL] × Fasting Glucose [mg/dL]) / 2)

Fasting Triglycerides

mg/dL

Fasting Glucose

mg/dL

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Obtain fasting triglycerides and fasting glucose

Collect fasting blood samples (patient fasted for at least 8-12 hours) and measure serum triglycerides in mg/dL and fasting plasma glucose in mg/dL. These are standard components of a basic metabolic panel and lipid panel, available from routine outpatient labs without any additional tests.

Calculate the TyG index

Apply the formula: TyG = ln (natural logarithm) of [(triglycerides mg/dL × fasting glucose mg/dL) / 2]. For example: TG = 150 mg/dL, glucose = 100 mg/dL: TyG = ln(150 × 100 / 2) = ln(7500) = 8.92. Higher TyG values indicate greater insulin resistance. The natural log transformation normalizes the skewed distribution of triglycerides and glucose.

Interpret TyG as a surrogate for insulin resistance

Higher TyG = greater insulin resistance. Proposed cutoffs vary by population and study: TyG >8.5-9.0 is commonly cited as elevated (insulin resistant), though no universally validated threshold exists. TyG is most useful as a relative comparator and research tool rather than a definitive clinical diagnostic threshold. Compare to population-specific reference values and interpret alongside BMI, waist circumference, HbA1c, and blood pressure.

Who Uses the TyG Index

Metabolic Syndrome Assessment Without Fasting Insulin

Primary care physicians, endocrinologists, cardiologists

TyG provides an insulin resistance estimate using only standard fasting labs (TG and glucose) — eliminating the need for fasting insulin assay, which is not standardized across labs and not widely available. This makes TyG practical for metabolic syndrome screening in routine outpatient settings.

PCOS Metabolic Evaluation

Gynecologists, endocrinologists, reproductive medicine specialists

Polycystic ovary syndrome (PCOS) is strongly associated with insulin resistance. TyG index can quantify the degree of insulin resistance in PCOS patients using readily available labs, guiding decisions about lifestyle intervention intensity and metformin therapy.

NAFLD/MASLD Screening Proxy

Hepatologists, gastroenterologists, primary care physicians

Elevated TyG correlates with non-alcoholic fatty liver disease (NAFLD/MASLD) risk and severity. TyG can serve as a non-invasive proxy for identifying patients who may benefit from liver imaging or elastography, particularly in patients with metabolic risk factors and elevated transaminases.

Cardiovascular Risk Assessment Beyond Standard Lipids

Cardiologists, preventive medicine physicians

TyG captures atherogenic insulin resistance not reflected by standard LDL-C measurement. Elevated TyG is associated with increased risk of atherosclerosis progression, PAD, and cardiovascular events, providing supplementary information to the ASCVD risk score in patients with metabolic syndrome or diabetes.

Population-Level Insulin Resistance Screening and Research

Epidemiologists, population health researchers, public health clinicians

TyG enables large-scale insulin resistance epidemiology studies using routinely collected metabolic data without requiring specialized insulin assays. It is widely used in observational studies examining cardiometabolic risk in diverse populations worldwide.

Pro Tips

TyG does not require fasting insulin — a key practical advantage

Unlike HOMA-IR (which requires fasting insulin measurement), TyG uses only fasting triglycerides and fasting glucose — both available from standard lipid panel and basic metabolic panel. Fasting insulin assays are not standardized across laboratories and vary in reference ranges. TyG provides comparable insulin resistance information to HOMA-IR (correlation r=0.62-0.92) without this limitation.

Fasting status is essential — TG and glucose rise significantly postprandially

Triglycerides increase substantially after a meal (by 50-300 mg/dL above fasting levels), and glucose rises postprandially. Using non-fasting values will significantly inflate the TyG index. Always confirm the patient fasted for at least 8-12 hours before sample collection. Non-fasting samples are invalid for TyG calculation.

No universally validated clinical cutoff exists

Published TyG cutoffs vary from 8.0 to 9.5 depending on the study, population, ethnicity, sex, and age group. There is no single universally accepted threshold for 'insulin resistant' equivalent to HOMA-IR >2.5. TyG is best interpreted in the context of population-specific reference data and in conjunction with other metabolic markers (waist circumference, HbA1c, BP). Avoid using a single cutoff as a clinical decision threshold.

TyG is associated with NAFLD, PAD, atherosclerosis, and diabetes risk

Multiple meta-analyses have confirmed TyG associations beyond insulin resistance: TyG predicts NAFLD/MASLD risk (Wu et al., J Hepatol 2020), peripheral artery disease, coronary artery calcium progression, new-onset type 2 diabetes, and major adverse cardiovascular events. These associations support TyG as a clinically relevant cardiometabolic marker.

Very elevated TG (>500 mg/dL) indicates severe hypertriglyceridemia beyond IR

When fasting TG >500 mg/dL, the primary concern shifts to severe hypertriglyceridemia (pancreatitis risk, chylomicronemia syndrome) rather than insulin resistance per se. TyG in this range is dominated by the extreme TG elevation. Investigate secondary causes (familial hypertriglyceridemia, hypothyroidism, severe diabetes, medications) and treat TG aggressively with fibrates or omega-3 fatty acids.

TyG-BMI provides better metabolic risk discrimination than TyG alone

TyG combined with BMI (TyG-BMI = TyG × BMI) has been shown to improve discrimination for metabolic syndrome, insulin resistance, and NAFLD compared to TyG alone in several studies. This reflects the independent contribution of visceral adiposity to metabolic risk. TyG-BMI may be more informative than TyG in clinical assessments.

TyG is a RESEARCH-VALIDATED surrogate — not a clinical decision-making threshold

TyG has strong research validation as a population-level insulin resistance marker. However, it has not been prospectively validated in clinical trials as a treatment decision threshold — there are no clinical trials demonstrating that treating to a target TyG reduces cardiovascular events. Use TyG to identify patients who may benefit from metabolic intervention, but make treatment decisions based on established clinical criteria (diabetes diagnosis, HbA1c, waist circumference, BP, lipids).

Lifestyle interventions that improve TyG

TyG can be reduced through: (1) carbohydrate restriction — reduces both fasting TG and glucose; (2) regular aerobic exercise — improves insulin sensitivity and lowers TG; (3) Mediterranean diet — reduces TG and improves glucose; (4) weight loss — 5-10% body weight reduction significantly reduces TyG. SGLT2 inhibitors and GLP-1 agonists also improve TyG by reducing both TG and glucose, making them particularly beneficial for TyG-elevated patients with T2DM.

Compare TyG with HOMA-IR when fasting insulin is available

If fasting insulin is available, calculate HOMA-IR [fasting glucose (mg/dL) × fasting insulin (µU/mL) / 405] alongside TyG. High concordance between HOMA-IR and TyG validates the TyG estimate. Discordance (e.g., high TyG but normal HOMA-IR) may occur in familial hypertriglyceridemia without true insulin resistance — in this case, clinical context and other metabolic markers should guide interpretation.

Common Questions About Your Results

There is no single universally validated cutoff. Published thresholds range from TyG >8.0 to >9.0+ depending on the study population, ethnicity, sex, age, and which reference standard (HOMA-IR, euglycemic clamp) was used for comparison. The most frequently cited cutoff in the literature is approximately 8.5-9.0, but this varies. TyG should be interpreted as a continuous variable with higher values indicating greater insulin resistance risk rather than applying a single binary threshold.

TyG is a reasonable surrogate for HOMA-IR in research and population screening contexts, with correlation coefficients of 0.62-0.92 depending on the population. For individual clinical diagnosis of insulin resistance, HOMA-IR is still more widely referenced in clinical guidelines and has more established clinical cutoffs (HOMA-IR >2.5 or >3.0). TyG is most appropriate when fasting insulin is unavailable and should be interpreted alongside other metabolic markers.

Yes. TyG values differ significantly by sex (women typically have lower TG and different glucose metabolism patterns) and by ethnicity (South Asian populations have higher insulin resistance at lower BMI, which affects TyG interpretation). Studies from East Asian, South Asian, Latin American, and European populations report different TyG thresholds for the same metabolic endpoints. Population-specific reference data should be used when available, and caution is warranted when applying cutoffs from one population to another.

TyG has not been prospectively validated as a treatment target in clinical trials. No randomized controlled trials have specifically enrolled patients based on elevated TyG and shown cardiovascular event reduction by treating to a TyG target. However, the underlying conditions TyG represents — elevated triglycerides, insulin resistance, and hyperglycemia — do have validated treatment benefits. Treat the underlying metabolic syndrome components (lifestyle modification, metformin, SGLT2 inhibitors, fibrates for severe hypertriglyceridemia) based on clinical criteria.

Evidence-Based Methodology

TyG Index proposed by Simental-Mendía et al. (Eur J Clin Invest 2008) as surrogate for insulin resistance. Correlation with HOMA-IR confirmed in meta-analyses: Guerrero-Romero et al. (Eur J Endocrinol 2010). TyG and cardiovascular events: Sanchez-Garcia et al. (Cardiovasc Diabetol 2020), meta-analysis of 11 studies, n=30,132. TyG and NAFLD: Wu et al. (J Hepatol 2020), meta-analysis. TyG-BMI: Er et al. (J Clin Endocrinol Metab 2020). No universally validated clinical cutoff; individual use requires caution. Not yet validated as RCT-level treatment target.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

The TyG index provides a practical insulin resistance signal based on routine fasting labs. Lower values tend to align with lower metabolic risk, while higher values are associated with insulin resistance, metabolic syndrome, and elevated cardiovascular risk in many cohorts.

When to Use This Tool

Use this calculator when fasting triglyceride and fasting glucose values are available and you want a quick, low-cost proxy for insulin resistance in outpatient screening, preventive cardiology, or metabolic follow-up.

Limitations

TyG thresholds are not universally standardized and vary across ethnicity, age, and study design. The index should not be used as a stand-alone diagnostic test for diabetes or metabolic syndrome.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Endocrinology

HOMA-IR

Estimate insulin resistance using fasting glucose and fasting insulin with the HOMA-IR equation.

Open Cardiology

Cholesterol Ratio

Calculate total cholesterol/HDL ratio and triglyceride/HDL ratio from a standard lipid panel. A total/HDL ratio below 3.5 is optimal. For full cardiovascular risk assessment, use [ASCVD Risk Calculator](/tools/ascvd-risk) or [Framingham Risk Score](/tools/framingham-risk).

Open Cardiology

ASCVD Risk Calculator

Estimate 10-year ASCVD risk using the 2013 ACC/AHA Pooled Cohort Equations, with the risk thresholds from the 2018 AHA/ACC cholesterol guideline.

Open

Frequently Asked Questions

The Triglyceride-Glucose (TyG) index is a mathematical surrogate for insulin resistance calculated from fasting triglycerides and fasting glucose using the formula: TyG = ln[(triglycerides mg/dL × fasting glucose mg/dL) / 2]. It was proposed by Simental-Mendía et al. (2008) as a practical alternative to HOMA-IR when fasting insulin is unavailable. Higher TyG values indicate greater insulin resistance and cardiometabolic risk.

There is no single universally established normal range. Most population studies suggest TyG values below approximately 8.5 indicate lower insulin resistance risk, with values above 8.5-9.0 indicating elevated insulin resistance risk. However, cutoffs vary significantly by population, sex, and ethnicity. A TyG of 8.0-8.5 might be average in some populations and elevated in others. Interpret TyG as a continuous variable — higher values consistently indicate more insulin resistance.

TyG correlates strongly with HOMA-IR (r = 0.62-0.92 in different studies) and euglycemic clamp-derived insulin sensitivity. TyG's key advantage is that it requires only fasting TG and glucose — no fasting insulin assay needed. HOMA-IR has more clinical guideline validation and standardized thresholds. In research settings, TyG is preferred for large cohort studies. For individual clinical assessment, HOMA-IR or glucose tolerance testing remain gold standards.

Elevated TyG (generally >8.5-9.0, with population-specific variation) suggests insulin resistance — the condition in which cells respond poorly to insulin, requiring higher insulin levels to maintain glucose homeostasis. Insulin resistance is associated with: type 2 diabetes risk, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD/MASLD), polycystic ovary syndrome (PCOS), cardiovascular disease risk, and atherogenic dyslipidemia (high TG, low HDL, small dense LDL). It indicates a cluster of cardiometabolic risk factors requiring lifestyle and possibly pharmacological intervention.

Yes. TyG is highly relevant in metabolic syndrome assessment because it directly captures two of the five metabolic syndrome criteria (elevated fasting TG and elevated fasting glucose). Multiple studies have confirmed that TyG is significantly higher in patients with metabolic syndrome and correlates with the number of metabolic syndrome components. TyG can serve as a quick, integrated metabolic risk marker when a full metabolic syndrome workup is not available.

Online Medical Tools — TyG Index

TyG Index

How It Works

Obtain fasting triglycerides and fasting glucose

Calculate the TyG index

Interpret TyG as a surrogate for insulin resistance

Who Uses the TyG Index

Metabolic Syndrome Assessment Without Fasting Insulin

PCOS Metabolic Evaluation

NAFLD/MASLD Screening Proxy

Cardiovascular Risk Assessment Beyond Standard Lipids

Population-Level Insulin Resistance Screening and Research

Pro Tips

TyG does not require fasting insulin — a key practical advantage

Fasting status is essential — TG and glucose rise significantly postprandially

No universally validated clinical cutoff exists

TyG is associated with NAFLD, PAD, atherosclerosis, and diabetes risk

Very elevated TG (>500 mg/dL) indicates severe hypertriglyceridemia beyond IR

TyG-BMI provides better metabolic risk discrimination than TyG alone

TyG is a RESEARCH-VALIDATED surrogate — not a clinical decision-making threshold

Lifestyle interventions that improve TyG

Compare TyG with HOMA-IR when fasting insulin is available

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

HOMA-IR

Cholesterol Ratio

ASCVD Risk Calculator

Further Reading

A Complete Guide to Cardiology: Risk Scores, Heart Failure, and Cardiovascular Disease Management

Frequently Asked Questions